Quagen Company Profile
What is the competitive landscape for QUAGEN
QUAGEN has eighty-two approved drugs.
There is one US patent protecting QUAGEN drugs.
Summary for Quagen
| US Patents: | 1 |
| Tradenames: | 67 |
| Ingredients: | 63 |
| NDAs: | 82 |
Drugs and US Patents for Quagen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Quagen | PROMETHAZINE HYDROCHLORIDE | promethazine hydrochloride | TABLET;ORAL | 040673-002 | Mar 5, 2008 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Quagen | CYPROHEPTADINE HYDROCHLORIDE | cyproheptadine hydrochloride | SYRUP;ORAL | 212423-001 | May 22, 2019 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Quagen | ALBUTEROL SULFATE | albuterol sulfate | SYRUP;ORAL | 212197-001 | Sep 6, 2019 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Quagen | PROMETHAZINE HYDROCHLORIDE | promethazine hydrochloride | TABLET;ORAL | 040673-001 | Mar 5, 2008 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Quagen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Quagen | OLUX E | clobetasol propionate | AEROSOL, FOAM;TOPICAL | 022013-001 | Jan 12, 2007 | 7,029,659 | ⤷ Start Trial |
| Quagen | EVOCLIN | clindamycin phosphate | AEROSOL, FOAM;TOPICAL | 050801-001 | Oct 22, 2004 | 7,141,237 | ⤷ Start Trial |
| Quagen | LUXIQ | betamethasone valerate | AEROSOL, FOAM;TOPICAL | 020934-001 | Feb 28, 1999 | 7,078,058 | ⤷ Start Trial |
| Quagen | OLUX E | clobetasol propionate | AEROSOL, FOAM;TOPICAL | 022013-001 | Jan 12, 2007 | 6,730,288 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for QUAGEN drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Topical Foam | 0.05% | ➤ Subscribe | 2005-06-27 |
| ➤ Subscribe | Foam | 0.12% | ➤ Subscribe | 2007-08-10 |
International Patents for Quagen Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 200702702 | ⤷ Start Trial |
| Japan | 4972553 | ⤷ Start Trial |
| Argentina | 051197 | ⤷ Start Trial |
| Russian Federation | 2381023 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Quagen Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1581193 | SPC/GB12/047 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727 |
| 1429780 | SPC/GB12/058 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 |
| 1304992 | 92401 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE |
| 1304992 | CR 2013 00053 | Denmark | ⤷ Start Trial | PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
